Intracerebral hemorrhage (ICH), which accounts for 10-20% of all strokes, has been modeled in the laboratory by intracerebral injection of autologous blood, injection of embolus, or proteolysis of the basal lamina surrounding brain capillaries by bacterial collagenase. The choice of model depends on the pathophysiological concept underlying the hemorrhage. Collagenase is a metalloprotease that degrades type IV collagen in the basal lamina of the blood-brain barrier, ultimately leading to microvascular rupture and leakage around the needle site. The collagenase injection model requires the injection of various amounts (0.01-0.1 units in 0.5-2 mL) of bacterial collagenase into the rat striatum.
Fig. 1. Collagenase-induced intracerebral hemorrhage in a murine model. (Lauer et al., 2013)
Ace Therapeutics offers collagenase injection-induced ICH models to support your preclinical research on hemorrhagic stroke.
The basic step in the construction of our collagenase injection model is the stereotaxic injection of 0.075U bacterial (Clostridia) collagenase dissolved in 0.5 μL saline into brain regions of rats or mice, causing specific brain parenchymal or intraventricular hemorrhage. We can also design a custom package with the amount of collagenase injected based on the severity of the hematoma. Our expert team is well-versed in stereotactic-assisted surgery, ensuring precise and reproducible injections of blood or collagenase into targeted brain areas.
Our laboratory can evaluate morphological and behavioral changes in animals with collagenase-induced ICH to ensure adequate performance of the procedure, or to investigate the effects of potential treatments.
We help our clients conduct a variety of studies in collagenase injection-induced ICH models, including
At Ace Therapeutics, our collagenase injection-induced ICH model provides a more comprehensive approach to support your hemorrhagic stroke preclinical research. Need to know more? Contact us and let one of our experts provide you with all the answers you need.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.